Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04585945 · ClinicalTrials.gov registry record
COVID-19 on Placental Gene Expression and Pathology
A clinical trial, sponsored by Prisma Health-Upstate.
- Completed
- Registry status
- 68
- Enrollment target
NCT04585945 is a clinical trial that has completed, run by Prisma Health-Upstate. The registered enrollment target is 68 participants.
The verdict
NCT04585945 has completed, sponsored by Prisma Health-Upstate.
- COMPLETED
- Registry status
- 68 participants
- Enrollment target
Study Summary
Little is known regarding the effect of antenatal COVID-19 on pregnancy outcomes. The purpose of this study is to determine of COVID-19 alters histopathology and gene expression of the placenta, as evidenced by analysis at time of delivery. The analysis will aim to identify whether resulting abnormal placental pathology or altered metabolism is associated with severity of symptoms (specifically pneumonia, or need for admission), gestational age at onset, and/or placenta efficiency. Histological and gene expression analysis of the placental post-delivery will determine if COVID-19 alters overall placental structure, vascularization, and/or the transcriptome.
Interventions
- DIAGNOSTIC_TEST Positive for SARS-CoV-2 infection
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 68 participants |
| Start Date | 2020-08-04 |
| Est. Completion | 2022-02-28 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04585945
The ClinicalTrials.gov registry entry for NCT04585945 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 68 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Prisma Health-Upstate, which has 67 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Positive for SARS-CoV-2 infection is the first listed.
NCT04585945 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04585945 about?
NCT04585945 is a clinical study titled "COVID-19 on Placental Gene Expression and Pathology". Little is known regarding the effect of antenatal COVID-19 on pregnancy outcomes. The purpose of this study is to determine of COVID-19 alters histopathology and gene expression of the placenta, as evidenced by analysis at time of delivery. The analysis will aim to identify whether resulting abnorma...
What is the current status of trial NCT04585945?
This trial is currently completed. The enrollment target is 68 participants. The study started on 2020-08-04. Estimated completion is 2022-02-28.
What interventions are being tested in trial NCT04585945?
The interventions under investigation include: Positive for SARS-CoV-2 infection (DIAGNOSTIC_TEST).
Who is sponsoring clinical trial NCT04585945?
This trial is sponsored by Prisma Health-Upstate, which has 67 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.